Opportunity Information: Apply for RFA DE 25 003
The TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) funding opportunity (RFA-DE-25-003) is a National Institutes of Health (NIH) cooperative agreement (U54) designed to build and operate a national, interdisciplinary research consortium focused on Temporomandibular Disorders (TMDs). The core purpose is to speed progress across the full pipeline of TMD research, from basic science discoveries to clinical research and, ultimately, translation into evidence-based treatments and better clinical care. A key emphasis is patient-centered translational research, meaning the consortium is expected to align research priorities, study designs, and outcomes with the needs and lived experiences of people affected by TMDs, while also producing results that can realistically be implemented in real-world healthcare settings.
Because this is a U54 cooperative agreement, applicants should expect substantial NIH involvement beyond standard grant oversight. In practice, that typically means NIH program staff are active partners in shaping consortium activities, coordinating multi-site efforts, and ensuring that shared goals, milestones, and deliverables are met across participating components. The notice also states "Clinical Trial Optional," indicating that applicants may propose clinical trials if they fit the program goals, but a clinical trial is not required for every proposed project. The overall structure is intended to support coordinated, team-based science rather than isolated projects, with an emphasis on collaboration, harmonization of methods, and producing outputs that move the field forward in a unified way.
The consortium is expected to advance several interconnected areas: basic and clinical TMD research, research training, and translation to improved care. This suggests an integrated program that not only generates new knowledge (for example, mechanisms of pain, tissue biology, neural pathways, biopsychosocial contributors, or risk stratification) but also strengthens the workforce and infrastructure needed to sustain TMD research nationally. The translational focus implies attention to developing and validating interventions, improving diagnostics or phenotyping approaches, identifying clinically meaningful outcomes, and closing the gap between research findings and routine clinical practice. The patient-centered angle also signals the importance of outcomes that matter to patients (such as pain interference, function, quality of life, and treatment burden), and potentially the inclusion of patient partners in governance, priority-setting, and dissemination.
Eligibility is broad and includes many types of U.S.-based organizations. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; tribal organizations other than federally recognized tribal governments; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses. The opportunity explicitly calls out additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions. These inclusions reinforce the intent to build a truly national effort and to encourage participation from institutions that serve diverse populations and communities.
At the same time, the FOA places clear limits on foreign participation. Non-domestic (non-U.S.) entities (foreign organizations) are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are also not eligible to apply. However, foreign components are allowed as defined in the NIH Grants Policy Statement, which generally means a U.S. applicant may include certain foreign elements when they are justified, well integrated, and necessary for the science (for example, a specific expertise, assay capability, or population access not available domestically), subject to NIH rules and approval.
Administratively, the opportunity is categorized as discretionary funding and uses the cooperative agreement mechanism. It is associated with multiple CFDA numbers (93.121, 93.213, 93.286, 93.313, 93.846, 93.853), reflecting NIH program areas that may support the initiative. The posting lists an original closing date of 2025-01-10 and a creation date of 2024-10-18. The award ceiling and expected number of awards are not specified in the provided summary, which typically means applicants should consult the full announcement for budget structure, allowable costs, anticipated award size, number of awards, project period, and any required consortium components (such as a coordinating center, data management, governance plans, or specific required cores).
Overall, TMD IMPACT is meant to create a coordinated national platform for TMD research that is interdisciplinary, collaborative, and grounded in patient needs, with the explicit goal of producing stronger evidence and accelerating the uptake of effective treatments into clinical care. Applicants considering this FOA should be prepared to propose a consortium-ready program with clear plans for collaboration, shared standards, training and capacity-building, and a translation pathway that connects research outputs to practical improvements in how TMDs are diagnosed, managed, and treated.Apply for RFA DE 25 003
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.286, 93.313, 93.846, 93.853.
- This funding opportunity was created on 2024-10-18.
- Applicants must submit their applications by 2025-01-10. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs): TMD IMPACT (RFA-DE-25-003)
What is the TMD IMPACT funding opportunity?
TMD IMPACT (The TMD Collaborative for IMproving PAtient-Centered Translational Research), RFA-DE-25-003, is an NIH cooperative agreement (U54) intended to build and operate a national, interdisciplinary research consortium focused on Temporomandibular Disorders (TMDs).
What is the main purpose of this program?
The core purpose is to accelerate progress across the full pipeline of TMD research, from basic science discoveries to clinical research and translation into evidence-based treatments and improved clinical care.
What does "patient-centered translational research" mean in this FOA?
It means the consortium is expected to align research priorities, study designs, and outcomes with the needs and lived experiences of people affected by TMDs, and to produce results that can realistically be implemented in real-world healthcare settings.
What activity code and funding mechanism does this opportunity use?
This opportunity uses the U54 cooperative agreement mechanism.
What does it mean that this is a cooperative agreement (U54)?
A U54 cooperative agreement generally involves substantial NIH involvement beyond standard grant oversight. NIH program staff may serve as active partners in shaping consortium activities, coordinating multi-site efforts, and helping ensure shared goals, milestones, and deliverables are met across participating components.
Is a clinical trial required?
No. The FOA is labeled "Clinical Trial Optional," meaning clinical trials may be proposed if they fit program goals, but a clinical trial is not required for every proposed project.
What kind of research is the consortium expected to support?
The consortium is expected to advance interconnected areas including basic and clinical TMD research, research training, and translation to improved care.
What are examples of scientific topics that fit the program's scope (based on the summary)?
Examples mentioned in the summary include mechanisms of pain, tissue biology, neural pathways, biopsychosocial contributors, and risk stratification, along with work tied to interventions, diagnostics/phenotyping, clinically meaningful outcomes, and bridging research findings into routine clinical practice.
What does the FOA emphasize about collaboration and how projects should be organized?
The structure is intended to support coordinated, team-based science rather than isolated projects, with emphasis on collaboration, harmonization of methods, and producing outputs that move the field forward in a unified way.
How does translation to improved care show up in expectations for the consortium?
The translational focus implies attention to developing and validating interventions, improving diagnostics or phenotyping approaches, identifying clinically meaningful outcomes, and closing the gap between research findings and routine clinical practice.
What kinds of outcomes are highlighted as important from a patient-centered perspective?
The summary highlights outcomes that matter to patients, such as pain interference, function, quality of life, and treatment burden.
Are patient partners expected to be involved?
The summary signals the importance of patient-centered governance and dissemination and suggests patient partners may be included in governance, priority-setting, and dissemination activities.
Who is eligible to apply?
Eligibility is broad for U.S.-based organizations and includes state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; tribal organizations other than federally recognized tribal governments; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses.
Are minority-serving institutions and other special categories of organizations eligible?
Yes. The opportunity explicitly calls out eligibility for Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, eligible federal agencies, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions.
Can a non-U.S. organization apply as the main applicant?
No. Non-domestic (non-U.S.) entities (foreign organizations) are not eligible to apply as the applicant organization.
Can a non-U.S. component of a U.S. organization apply?
No. Non-domestic components of U.S. organizations are also not eligible to apply.
Are foreign components allowed at all?
Yes. Foreign components are allowed as defined in the NIH Grants Policy Statement. In general, that means a U.S. applicant may include certain foreign elements when justified, well integrated, and necessary for the science, subject to NIH rules and approval.
What is meant by "foreign component" in this context (at a high level)?
Based on the summary, a foreign component could involve foreign expertise, specialized assay capability, or population access not available domestically, as long as it is necessary for the science and fits NIH policy requirements.
What type of funding is this categorized as?
The opportunity is categorized as discretionary funding and uses the cooperative agreement mechanism.
Are CFDA numbers provided for this opportunity?
Yes. The summary lists multiple CFDA numbers associated with this initiative: 93.121, 93.213, 93.286, 93.313, 93.846, and 93.853.
What is the closing date and when was the opportunity created?
The posting lists an original closing date of 2025-01-10 and a creation date of 2024-10-18.
Is the award ceiling provided in the summary?
No. The award ceiling is not specified in the provided summary.
Is the expected number of awards provided in the summary?
No. The expected number of awards is not specified in the provided summary.
What should applicants do if they need details on budget, award size, or required components?
Because the summary does not specify the budget structure, allowable costs, anticipated award size, number of awards, project period, or any required consortium components, applicants should consult the full announcement for those details.
What kinds of consortium infrastructure or components might be relevant to plan for (based on the summary's language)?
The summary indicates applicants should be prepared for a consortium-ready program with clear plans for collaboration, shared standards, training and capacity-building, and a translation pathway. It also notes that full announcements often describe required consortium components such as a coordinating center, data management, governance plans, or specific required cores.
What is the overall goal of creating a national TMD research consortium?
The overall goal is to create a coordinated national platform for TMD research that is interdisciplinary, collaborative, and grounded in patient needs, producing stronger evidence and accelerating the uptake of effective treatments into clinical care.
How should applicants think about the role of NIH staff during the project?
Applicants should expect NIH program staff to be active partners (beyond standard oversight) in guiding consortium activities, coordinating multi-site efforts, and supporting progress toward shared milestones and deliverables.
Does this FOA favor isolated projects or integrated programs?
The summary emphasizes coordinated, team-based, harmonized work across the consortium rather than isolated projects.
What does the national and interdisciplinary emphasis imply for applicant teams?
It implies building a consortium capable of multi-site, interdisciplinary collaboration, with harmonized methods and shared goals that advance TMD research and translation in a unified way.
Browse more opportunities from the same category: Health
Next opportunity: The Nita M. Lowey Middle East Partnership for Peace Act (MEPPA)
Previous opportunity: Advancing Health Equity through Interventions to Prevent and Address Housing Instability (R01 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DE 25 003
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DE 25 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional) Apply for PAR 25 120 Funding Number: PAR 25 120 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Comprehensive Analysis, Surveillance, and Statistics Initiative for Diabetes in the Young (CASSIDY) Apply for RFA DP 25 043 Funding Number: RFA DP 25 043 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $700,000 |
| Connecting Organizations and People to Empower Diabetes Prevention and Treatment (Connections) Apply for RFA DP 25 041 Funding Number: RFA DP 25 041 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $350,000 |
| Epilepsy Incidence Among Children in the United States Apply for RFA DP 25 038 Funding Number: RFA DP 25 038 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $500,000 |
| Advancing Public Health Actions to Prevent and Control Chronic Disease in the U.S. Territories and Freely Associated States Apply for CDC RFA DP 25 0024 Funding Number: CDC RFA DP 25 0024 Agency: Centers for Disease Control - NCCDPHP Category: Health Funding Amount: $1,400,000 |
| Centers of Excellence in Maternal and Child Health Education, Science, and Practice Apply for HRSA 25 027 Funding Number: HRSA 25 027 Agency: Health Resources and Services Administration Category: Health Funding Amount: $366,769 |
| Maternal and Child Health Public Health Catalyst Program Apply for HRSA 25 025 Funding Number: HRSA 25 025 Agency: Health Resources and Services Administration Category: Health Funding Amount: $135,000 |
| Behavioral Health Workforce Education and Training Program for Professionals Apply for HRSA 25 068 Funding Number: HRSA 25 068 Agency: Health Resources and Services Administration Category: Health Funding Amount: $600,000 |
| Graduate Psychology Education Program (GPE) Apply for HRSA 25 067 Funding Number: HRSA 25 067 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) Apply for PAR 25 058 Funding Number: PAR 25 058 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) Apply for PAR 25 059 Funding Number: PAR 25 059 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) Apply for PAR 25 060 Funding Number: PAR 25 060 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Centers for Accelerating Phage (Bacteriophage) Therapy to Combat ESKAPE Pathogens (CAPT-CEP) (P01 Clinical Trial Not Allowed) Apply for RFA AI 24 069 Funding Number: RFA AI 24 069 Agency: National Institutes of Health Category: Health Funding Amount: $1,200,000 |
| Pilot projects to enhance utility and usage of data sets from the Molecular Transducers of Physical Activity Consortium (MoTrPAC) (R03 Clinical Trials Not allowed) Apply for RFA RM 24 011 Funding Number: RFA RM 24 011 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) Apply for PAR 25 057 Funding Number: PAR 25 057 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Human Virome Program: Developing novel and innovative tools to interrogate and annotate the human virome (U01 Clinical Trial Not Allowed) Apply for RFA RM 24 009 Funding Number: RFA RM 24 009 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Strengthening Malaria Control for High-Risk Communities Apply for 72048225RFA00002 Funding Number: 72048225RFA00002 Agency: Thailand USAID-Bangkok Category: Health Funding Amount: $15,000,000 |
| Implementation Research for Multi-morbidity Management in the Context of Non-communicable Diseases in Low- and Middle-Income Countries and US Tribal Populations (R61/R33 Clinical Trial Required) Apply for PAR 25 223 Funding Number: PAR 25 223 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R01 Clinical Trial Not Allowed) Apply for PAR 25 076 Funding Number: PAR 25 076 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Limited Competition: Renewal of Existing NINDS-Supported Clinical Trial Cooperative Agreement Awards (U01 - Clinical Trials Required) Apply for PAR 25 149 Funding Number: PAR 25 149 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DE 25 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.